On Friday, Shares of Citigroup Inc. (NYSE:C), lost -2.32% to $50.59.
Citigroup signed a contract with Erste Bank Hungary Zrt. and its partner Erste Befektetési Zrt. (Erste Investment) to sell its consumer banking business in Hungary. The sale comprises Citi’s retail banking, consumer loans, cards businesses and the transfer of consumer banking employees. This transaction is subject to regulatory approvals, which are predictable by the end of 2015. Transfer of customer accounts is predictable to be accomplished in Q4 2016. The financial terms of the transaction are not material to Citi.
Citi will remain in Hungary and intends to focus on expanding the services it offers to Hungarian corporations, financial institutions, and public sector clients. Citi will continue to service its multi-national clients with operations in Hungary. Citi also remains committed to operating and expanding its Citi Service Center located in Budapest, presently serving over 50 countries worldwide.
Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -2.47% to $57.30, during its last trading session.
Bristol-Myers Squibb Company declared data from its Immuno-Oncology clinical development programs to be presented at the 16th World Conference on Lung Cancer (WCLC) in Denver, CO from September 6-9. The company is presenting Opdivo (nivolumab) data in a broad set of patients with lung cancer, across histologies and treatment settings. These data add to the growing body of evidence that may assist the scientific community advance their understanding Opdivo’s role in the treatment of lung cancer as a single agent and its potential in combination with Yervoy (ipilimumab). Key oral presentations comprise:
- CheckMate -012, September 7 during the 10:45am -12:15pm MDT Session: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer
- CheckMate -017, September 7 during the 10:45am -12:15pm MDT Session: Phase 3, Randomized Trial of Nivolumab vs Docetaxel in Advanced Squamous Cell Non-Small Cell Lung Cancer
- CheckMate -063, September 7 during the 10:45am -12:15pm MDT Session: Longer-Term Follow-Up of a Phase 2 Study of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
- CheckMate -153, September 7 during the 10:45am -12:15pm MDT Session: Safety and Efficacy of Nivolumab in an Ongoing Trial of a PD-L1+/- Patient Population with Metastatic Non-Small Cell Lung Cancer
- CheckMate -017, September 9 during the 9:00am - 4:45 p.m. MDT Session: Evaluation of Disease-Related Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Sysco Corporation (NYSE:SYY), ended its last trade with -0.85% loss, and closed at $39.57.
Sysco Corporation declared that its Board of Directors declared a regular quarterly cash dividend of $0.30 per share, payable on October 23, 2015, to common shareholders of record at the close of business on October 2, 2015.
Sysco Corporation, through its auxiliaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry. It distributes a line of frozen foods, such as meats, seafood, fully prepared entrees, fruits, vegetables, and desserts; a line of canned and dry foods; fresh meats and seafood; dairy products; beverage products; imported specialties; and fresh produce.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
